BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27154568)

  • 1. Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer.
    Lee JY; Park KS; Lee HG; Baek WK; Cho KB; Lee YJ; Lee YS; Ryu SW
    Clin Exp Med; 2017 Aug; 17(3):403-410. PubMed ID: 27154568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening.
    Aikou S; Ohmoto Y; Gunji T; Matsuhashi N; Ohtsu H; Miura H; Kubota K; Yamagata Y; Seto Y; Nakajima A; Goldenring JR; Kaminishi M; Nomura S
    Gastroenterology; 2011 Sep; 141(3):837-845.e1-7. PubMed ID: 21699780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk.
    Kaise M; Miwa J; Tashiro J; Ohmoto Y; Morimoto S; Kato M; Urashima M; Ikegami M; Tajiri H
    J Gastroenterol; 2011 Jun; 46(6):736-45. PubMed ID: 21455714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China.
    Huang Z; Zhang X; Lu H; Wu L; Wang D; Zhang Q; Ding H
    BMC Gastroenterol; 2014 Apr; 14():74. PubMed ID: 24720760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker.
    Kaise M; Miwa J; Fujimoto A; Tashiro J; Tagami D; Sano H; Ohmoto Y
    Gastric Cancer; 2013 Jul; 16(3):329-37. PubMed ID: 22907485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of serum pepsinogen levels and quininium resin test combined for gastric cancer screening.
    Kim JR; Lee K; Jung WT; Lee OJ; Kim TH; Kim HJ; Lee JS; Passaro DJ
    Cancer Detect Prev; 2005; 29(6):570-5. PubMed ID: 16289505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening Biomarker as an Alternative to Endoscopy for the Detection of Early Gastric Cancer: The Combination of Serum Trefoil Factor Family 3 and Pepsinogen.
    Lee HS; Jeon SW; Nomura S; Seto Y; Kwon YH; Nam SY; Ishibashi Y; Ohtsu H; Ohmoto Y; Yang HM
    Gastroenterol Res Pract; 2018; 2018():1024074. PubMed ID: 29977284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.
    Choi HS; Lee SY; Kim JH; Sung IK; Park HS; Shim CS; Jin CJ
    J Dig Dis; 2014 Jun; 15(6):293-8. PubMed ID: 24602176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on the cut-off value of serum pepsinogen abnormality for screening chronic atrophic gastritis and gastric carcinoma].
    Li YH; Zhang XH; Huang B; Wang JL; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Oct; 27(10):840-4. PubMed ID: 17343174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of serum pepsinogen level and gastric mucosal changes of residents in the high incidence area of gastric cancer].
    Zhang XH; Huang B; Wang JL; Li YH; Mi JM; Shen HT; Zhang ZG; Yan X; Xing LX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):507-11. PubMed ID: 17147114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis.
    Haj-Sheykholeslami A; Rakhshani N; Amirzargar A; Rafiee R; Shahidi SM; Nikbin B; Khosravi F; Massarrat S
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):174-9. PubMed ID: 18237867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum pepsinogen levels can quantify the risk of development of metachronous gastric cancer after endoscopic resection.
    Iguchi M; Kato J; Yoshida T; Yamamoto Y; Nakachi K; Fukatsu K; Mori Y; Maeda Y; Moribata K; Shingaki N; Niwa T; Deguchi H; Inoue I; Maekita T; Tamai H; Ichinose M
    Int J Cancer; 2016 Sep; 139(5):1150-6. PubMed ID: 27083518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of serum pepsinogen I , II and osteopontin co-detection in gastric cancer screening].
    Gong YH; Sun LP; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):691-3. PubMed ID: 17274377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis].
    Chae H; Lee JH; Lim J; Kim M; Kim Y; Han K; Kang CS; Shim SI; Kim JI; Park SH
    Korean J Lab Med; 2008 Jun; 28(3):201-6. PubMed ID: 18594172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric cancer screening using the serum pepsinogen test method.
    Miki K
    Gastric Cancer; 2006; 9(4):245-53. PubMed ID: 17235625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica.
    Con SA; Con-Wong R; Con-Chin GR; Con-Chin VG; Takeuchi H; ValerĂ­n AL; Echandi G; Mena F; Brenes F; Yasuda N; Araki K; Sugiura T
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2631-6. PubMed ID: 18086767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm.
    Boda T; Ito M; Yoshihara M; Kitamura Y; Matsuo T; Oka S; Tanaka S; Chayama K
    Helicobacter; 2014 Feb; 19(1):1-8. PubMed ID: 24215601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between pepsinogen I/II ratio and age or upper gastrointestinal diseases in Helicobacter pylori-positive and -negative subjects].
    Paik CN; Chung IS; Nam KW; Kwon JH; Chang JH; Suh JP; Park JM; Cho YK; Lee IS; Kim SW; Choi MG
    Korean J Gastroenterol; 2007 Aug; 50(2):84-91. PubMed ID: 17928751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
    Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
    Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.